HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $20.00 price target on the stock.

TransCode Therapeutics Stock Down 11.2 %

RNAZ stock opened at $0.91 on Thursday. TransCode Therapeutics has a one year low of $0.93 and a one year high of $66.33. The company has a fifty day moving average price of $5.65 and a two-hundred day moving average price of $241.35.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.